Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

As the new year sparks a wave of weight loss resolutions and millions turn to weight loss medications, rising costs and the ...

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...

On its way out the door, the Biden administration is proposing that Medicare and Medicaid cover Ozempic and other GLP-1 drugs ...

Starting next year, Medicare recipients will see a $2,000 out-of-pocket cap on some prescription drugs as part of several new provisions coming in 2025. Starting in 2025, Medicare recipients will ...

The British Medical Journal (BMJ) reported in 2024 that prescription ... Table 2. Medication-era mindset Don't enter the new GLP-1 medicine health and weight loss paradigm with an old mindset.

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking it the ...

Starting next year, Medicare recipients will see a $2,000 out-of-pocket cap on some prescription drugs as part of several new provisions coming in 2025. Starting in 2025, Medicare recipients will see ...